Phibro Animal Health Q3 FY2026: Sales $383.5M (+10%), Adj. EBITDA $60.8M (+11%); Guidance raised

PHIBRO ANIMAL HEALTH CORP

2026-Q3 EPS reported $1.90 revenue$1,121,346,000

Q3 net sales $383.5M, +10% YoY; Animal Health segment +13% to $291.2M, driven by MFA portfolio, nutritional specialties, vaccines.
Net income $24.0M, +15%; diluted EPS $0.59; adjusted diluted EPS $0.76, +19% YoY.
Updated FY2026 guidance: net sales $1.46B-$1.50B (14% growth), adjusted EBITDA $247M-$255M (37% growth).
Post-quarter: expanded revolver by $125M to $435M; announced Sustainable Solutions Platform with VERRATAIN; Brazil regulatory development on antimicrobials noted.
Gross margin improved 270 bps to 32.8%; free cash flow $12.8M trailing twelve months; leverage 3.1x.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PHIBRO ANIMAL HEALTH CORP reported third quarter ended March 31, 2026 results: revenue $383.5 million, net income $24.0 million, EPS $0.59. Guidance reaffirmed.

Period: third quarter ended March 31, 2026
Revenue: $383.5 million
Net income: $24.0 million
EPS: $0.59
Guidance: reaffirmed
Result: reported results

Exact text from the filing

guidance for the year ending June 30, 2026. Highlights for the three months ended March 31, 2026 (compared to the three months ended March 31, 2025): - Net sales of $383.5 million, an increase of $35.7 million, or 10% - Net income of $24.0 million, an increase of $3.1 million, or 15% - Diluted earnings per share of $0.59, an increase of $0.08, or 16% -

View on SEC.gov

Browse all earnings releases →

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001104659-26-056316

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.